Testosterone Enanthate Side Effects: Rare but Serious Adverse Events

What Makes a Testosterone Enanthate Side Effect "Rare but Serious"?

Adverse events from Testosterone Enanthate split into two practical buckets. Common effects (acne, injection-site reactions, mood shifts) are bothersome but rarely dangerous. Serious effects are low-frequency yet capable of causing permanent organ damage, hospitalization, or death. The FDA's current prescribing label for testosterone enanthate lists polycythemia, venous thromboembolism, cardiovascular events, hepatic effects, and sleep apnea under warnings requiring active clinical management. [1]

Frequency alone does not define severity. An event occurring in 1 in 500 patients can still mandate immediate dose cessation if it carries stroke-level consequences.

How the FDA Classifies These Warnings

The FDA uses a boxed-warning (black-box) system for the most severe risks and a standard "Warnings and Precautions" section for serious but non-boxed risks. Testosterone enanthate currently carries no black-box warning, but its label contains six formal Warnings and Precautions entries covering the events discussed in this article. [1]

Why Post-Market Data Matter Here

Pre-approval trials for testosterone enanthate enrolled relatively small, short-term cohorts. The FAERS database, published case series, and the 2023 TRAVERSE trial provide most of what clinicians now know about rare serious events. Rare events with incidence rates below 0.5% simply cannot be reliably detected in trials enrolling a few hundred participants.

Erythrocytosis and Polycythemia

Erythrocytosis (elevated red-cell mass, often measured as hematocrit above 50 to 54%) is the most frequently encountered serious adverse event in clinical practice with injectable testosterone therapy. [2]

How It Develops

Testosterone stimulates erythropoietin secretion from the kidney and acts directly on bone-marrow erythroid precursors. Injectable esters, including testosterone enanthate, produce higher peak serum testosterone than transdermal gels and therefore carry a higher erythrocytosis risk. A 2017 meta-analysis published in JAMA Internal Medicine found that injectable testosterone formulations produced clinically significant erythrocytosis in approximately 11% of treated men, compared with roughly 3% for transdermal preparations. [2]

Clinical Consequences

Hematocrit above 54% raises whole-blood viscosity and is associated with increased risk of ischemic stroke and deep-vein thrombosis. The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states: "We suggest checking hematocrit at baseline, at 3 to 6 months, and then annually; if hematocrit exceeds 54%, stop therapy until hematocrit decreases to a safe level." [3]

Monitoring Protocol

• Baseline hematocrit before first injection.
• Recheck at 3 months and 6 months.
• Annual checks thereafter if stable.
• Dose reduction or formulation switch if values trend between 50% and 54%.
• Phlebotomy is sometimes used in refractory cases, though evidence for this specific intervention is limited.

Cardiovascular Events: What TRAVERSE Actually Found

Cardiovascular risk dominated testosterone prescribing debates for over a decade. The TRAVERSE trial (N=5,246, median follow-up 22 months) was a randomized, placebo-controlled, double-blind study specifically designed to answer the question. [4]

The Primary TRAVERSE Outcome

The trial enrolled men aged 45 to 80 with confirmed hypogonadism (two morning testosterone values below 300 ng/dL) and either established cardiovascular disease or high cardiovascular risk. The primary endpoint was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Testosterone therapy did not significantly increase this primary MACE endpoint (hazard ratio 0.96, 95% CI 0.78 to 1.17; P<0.001 for non-inferiority). [4]

Secondary Findings That Raised Concern

TRAVERSE was not entirely reassuring. The trial found statistically significant increases in two secondary outcomes: atrial fibrillation (3.5% vs. 2.4% in placebo, P<0.001) and pulmonary embolism (0.9% vs. 0.5%, P=0.03). [4] These findings are particularly relevant for men with pre-existing arrhythmia risk or a history of thromboembolic disease.

Pre-TRAVERSE Context

Before TRAVERSE, a 2010 trial by Basaria et al. In NEJM was halted early when testosterone-treated men with mobility limitation and high comorbidity burden showed a higher rate of cardiovascular events (23 events in 106 testosterone recipients vs. 5 in 103 placebo recipients). [5] That trial enrolled an unusually frail population, limiting generalizability, but it drove years of regulatory scrutiny.

Venous Thromboembolism

The FDA added a formal VTE warning to all testosterone product labels in 2014 following a review of FAERS spontaneous reports. [6]

Mechanistic Basis

Testosterone and its metabolites influence coagulation pathways. Erythrocytosis-driven hyperviscosity is one pathway. Testosterone also appears to increase platelet aggregability and suppress fibrinolytic activity in some studies, though findings are not fully consistent across the literature.

Quantifying the Risk

A 2016 case-control study (N=39,622) published in BMJ found that men who filled a new testosterone prescription had a VTE odds ratio of 1.63 (95% CI 1.12 to 2.37) in the 6 months following initiation, compared with matched non-users. [7] The absolute risk increase was small, but a nearly 2-fold relative increase is clinically meaningful for patients with baseline VTE risk factors such as Factor V Leiden, obesity, or prolonged immobility.

Who Faces the Highest Risk

• Personal or family history of DVT or pulmonary embolism.
• Inherited thrombophilia (not always screened before TRT initiation).
• Hematocrit trending above 50%.
• Long-haul travel or surgical immobility during testosterone treatment.

Hepatic Effects

Serious hepatotoxicity from testosterone enanthate injections is uncommon, but the drug class carries a well-documented liver-injury profile that clinicians cannot ignore. [1]

Peliosis Hepatis and Hepatocellular Carcinoma

Peliosis hepatis (blood-filled cysts in the liver parenchyma) and hepatocellular carcinoma have been reported in patients receiving long-term androgen therapy. The preponderance of cases involve 17-alpha-alkylated oral androgens (e.g., oxymetholone, stanozolol) rather than injectable esters. However, the FDA label for testosterone enanthate retains these as possible adverse events, and isolated case reports of hepatic changes exist with injectable androgens at supraphysiologic doses. [1]

Cholestasis

Cholestatic jaundice has been reported with androgen therapy. Clinically, it presents as pruritus, jaundice, and elevated conjugated bilirubin. Resolution typically follows drug cessation. Baseline liver-function testing is not universally required for standard-dose TE, but should be obtained if the patient reports any symptoms of hepatic dysfunction.

Monitoring Guidance

The Endocrine Society 2018 guideline does not mandate routine LFT monitoring for injectable testosterone in the absence of symptoms, distinguishing injectable esters from hepatotoxic oral androgens. [3] Still, any symptom suggesting hepatic involvement (jaundice, right-upper-quadrant pain, unexplained fatigue) warrants immediate hepatic panel and drug hold.

Sleep Apnea Exacerbation

Testosterone therapy does not cause sleep apnea de novo in most patients, but it can substantially worsen pre-existing obstructive sleep apnea (OSA) and unmask subclinical disease. [1]

The Mechanism

Testosterone reduces the hypoxic ventilatory response and may alter upper-airway muscle tone. Both effects lower the arousal threshold during apneic episodes, lengthening desaturation events.

Observed Frequency

A randomized crossover study by Liu et al. In Journal of Clinical Endocrinology and Metabolism showed that supraphysiologic testosterone doses (600 mg/week of TE) increased apnea-hypopnea index significantly compared with placebo. [8] At therapeutic doses, the effect is less pronounced but still present in susceptible individuals.

Clinical Screening Recommendation

The 2018 Endocrine Society guideline explicitly states: "We recommend against initiating testosterone therapy in patients with untreated severe obstructive sleep apnea." [3] Pre-treatment screening with the STOP-BANG questionnaire (score ≥3 warrants further evaluation) is a practical minimum before starting TE in any adult male.

Suppression of Spermatogenesis and Fertility

This adverse event is not rare by frequency. It is serious by consequence, especially for men of reproductive age who have not completed family building. [9]

Mechanism of Suppression

Exogenous testosterone suppresses pituitary LH and FSH secretion through negative feedback on the hypothalamic-pituitary-gonadal axis. Without LH stimulation of Leydig cells and FSH stimulation of Sertoli cells, intratesticular testosterone collapses (falling from roughly 100-fold higher than serum to near-serum levels), and spermatogenesis halts.

Time Course and Reversibility

A landmark WHO multicenter trial of testosterone enanthate 200 mg/week as male contraception demonstrated that 65% of men reached azoospermia within 6 months. [9] The median time to recovery of sperm counts above 20 million/mL after stopping TE was 3.4 months, and 96% recovered within 18 months. Recovery is not guaranteed, particularly in men with pre-existing fertility compromise or after years of continuous use.

Practical Implications

Men considering parenthood should bank sperm before starting TE. Fertility-sparing alternatives include clomiphene citrate (off-label) or human chorionic gonadotropin-based protocols that preserve the HPG axis.

Prostate-Related Adverse Events

Testosterone enanthate is contraindicated in men with known or suspected prostate carcinoma. The concern is biological acceleration of androgen-sensitive prostate cancer growth, not de novo carcinogenesis. [1]

PSA Surveillance

A rise in PSA above 1.4 ng/mL above baseline within any 12-month period, or a PSA above 4.0 ng/mL at any single measurement, should trigger urology referral and temporary TE hold per current Endocrine Society guidance. [3] Benign prostatic hyperplasia symptoms can worsen with testosterone therapy and should be tracked using a validated tool such as the International Prostate Symptom Score.

Psychiatric and Neurological Rare Events

Serious psychiatric adverse events with testosterone at therapeutic doses are uncommon. At supraphysiologic doses, the picture changes considerably.

Aggressive Behavior and Mania

Case series and FAERS reports describe manic episodes, psychosis, and severe aggression in men using anabolic-androgenic steroids at doses far exceeding therapeutic TRT ranges. A systematic review in JAMA Psychiatry found that psychiatric symptoms were strongly dose-dependent, with most serious events occurring at doses above 500 mg/week. [10] Standard therapeutic TE (75 to 200 mg every 1 to 2 weeks) carries a substantially lower psychiatric signal, but clinicians should document baseline mood and screen for personal or family history of bipolar disorder before prescribing.

Priapism

Prolonged, painful erection (priapism) unrelated to sexual stimulation is a rare but urologic emergency. The mechanism involves altered nitric oxide and adrenergic receptor balance in penile vasculature. Immediate urologic evaluation is required for any erection lasting more than 4 hours.

Drug Interactions That Amplify Serious Risk

Two interaction classes deserve specific mention in any serious-adverse-event discussion.

Anticoagulants

Testosterone enanthate can potentiate the anticoagulant effect of warfarin. The FDA label notes that prothrombin time should be monitored frequently when TE is co-administered with anticoagulants, as dose reduction of the anticoagulant may be necessary. [1] This interaction is pharmacodynamic, not solely pharmacokinetic.

Insulin and Oral Hypoglycemics

Androgens improve insulin sensitivity. Men with diabetes or prediabetes starting TE may experience hypoglycemic episodes if their antidiabetic medication doses are not adjusted. Glucose monitoring should be increased in the first 8 to 12 weeks of therapy for any patient on insulin, sulfonylureas, or GLP-1 receptor agonists.

Recognizing and Reporting Serious Adverse Events

What Patients Should Do Immediately

Patients should seek emergency care or call 911 for chest pain, sudden shortness of breath (possible pulmonary embolism), one-sided weakness or speech difficulty (possible stroke), priapism, or sudden vision change. These presentations should not wait for a clinic callback.

Jaundice, leg swelling, or new-onset loud snoring with witnessed apnea episodes warrant same-day or next-day evaluation.

Reporting to FAERS

Both patients and providers can submit adverse event reports to the FDA MedWatch program at fda.gov/safety/medwatch. This reporting is voluntary but valuable; FAERS data contributed to the 2014 VTE label update across all testosterone products. [6]

Monitoring Schedule for Patients on Testosterone Enanthate

The following schedule is consistent with Endocrine Society 2018 guideline recommendations. [3]

| Timepoint | Tests | |---|---| | Baseline | Total testosterone (AM), hematocrit, PSA, LFTs (if indicated), STOP-BANG | | 3 months | Total testosterone (trough/mid-cycle), hematocrit, symptom review | | 6 months | Testosterone, hematocrit, PSA, blood pressure, weight | | 12 months | Full panel as above, bone density if osteoporosis risk present | | Annually thereafter | Hematocrit, PSA, testosterone level, lipid panel |